Phase 1/2 trial in 1015 adults aged 50+: solicited adverse events with low/mid/high-dose VAX-31 were 76%, 78%, 83% vs 71% with PCV20, mostly mild or moderate; no vaccine-related serious events. Secondary: mid and high doses met OPA non-inferiority for all 20 shared serotypes.
RCTn = 1,015
Wassil et al. Safety, tolerability, and immunogenicity of a 31-valent pneumococcal conjugate vaccine (VAX-31) in healthy adults aged 50 years and older from the USA: a phase 1/2, double-blinded, active-controlled, parallel-group, dose-finding randomised clinical trial